• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's After-Market Session

    1/16/24 4:31:08 PM ET
    $ALEC
    $ASLN
    $BCEL
    $CNSP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALEC alert in real time by email

    Gainers

    • Moleculin Biotech (NASDAQ:MBRX) shares moved upwards by 8.7% to $0.72 during Tuesday's after-market session. The market value of their outstanding shares is at $23.9 million.
    • Evoke Pharma (NASDAQ:EVOK) stock increased by 7.27% to $0.92. The company's market cap stands at $3.0 million.
    • TC BioPharm (Holdings) (NASDAQ:TCBP) shares rose 7.2% to $2.38. The market value of their outstanding shares is at $1.6 million.
    • CNS Pharma (NASDAQ:CNSP) stock increased by 6.45% to $0.76. The market value of their outstanding shares is at $4.7 million.
    • Atreca (NASDAQ:BCEL) stock increased by 6.29% to $0.27. The company's market cap stands at $10.6 million.
    • ASLAN Pharma (NASDAQ:ASLN) stock increased by 5.94% to $0.62. The company's market cap stands at $10.2 million.

    Losers

    • Savara (NASDAQ:SVRA) stock decreased by 11.9% to $3.75 during Tuesday's after-market session. The company's market cap stands at $507.5 million.
    • MyMD Pharmaceuticals (NASDAQ:MYMD) stock fell 9.22% to $0.18. The company's market cap stands at $9.3 million.
    • Alector (NASDAQ:ALEC) stock fell 8.38% to $7.0. The market value of their outstanding shares is at $588.9 million.
    • Enliven Therapeutics (NASDAQ:ELVN) shares declined by 6.98% to $11.07. The company's market cap stands at $456.2 million.
    • Estrella Immunopharma (NASDAQ:ESLA) stock declined by 6.26% to $1.2. The company's market cap stands at $42.2 million.
    • Trevena (NASDAQ:TRVN) stock declined by 4.97% to $0.65. The market value of their outstanding shares is at $11.2 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ALEC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALEC
    $ASLN
    $BCEL
    $CNSP

    CompanyDatePrice TargetRatingAnalyst
    Alector Inc.
    $ALEC
    3/10/2026$6.00Neutral → Buy
    BTIG Research
    Alector Inc.
    $ALEC
    10/22/2025$1.50Outperform → Neutral
    Mizuho
    Alector Inc.
    $ALEC
    10/22/2025Buy → Hold
    TD Cowen
    Alector Inc.
    $ALEC
    10/22/2025Overweight → Neutral
    Cantor Fitzgerald
    Alector Inc.
    $ALEC
    10/22/2025Outperform → Mkt Perform
    William Blair
    Alector Inc.
    $ALEC
    10/22/2025Buy → Neutral
    BTIG Research
    Savara Inc.
    $SVRA
    10/20/2025$7.00Overweight
    Wells Fargo
    Savara Inc.
    $SVRA
    8/15/2025$5.00Neutral → Buy
    H.C. Wainwright
    More analyst ratings

    $ALEC
    $ASLN
    $BCEL
    $CNSP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Alector upgraded by BTIG Research with a new price target

    BTIG Research upgraded Alector from Neutral to Buy and set a new price target of $6.00

    3/10/26 8:36:07 AM ET
    $ALEC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Alector downgraded by Mizuho with a new price target

    Mizuho downgraded Alector from Outperform to Neutral and set a new price target of $1.50

    10/22/25 7:10:52 AM ET
    $ALEC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Alector downgraded by TD Cowen

    TD Cowen downgraded Alector from Buy to Hold

    10/22/25 7:10:36 AM ET
    $ALEC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALEC
    $ASLN
    $BCEL
    $CNSP
    SEC Filings

    View All

    SEC Form 10-K filed by CNS Pharmaceuticals Inc.

    10-K - CNS Pharmaceuticals, Inc. (0001729427) (Filer)

    3/31/26 4:30:28 PM ET
    $CNSP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-3 filed by Moleculin Biotech Inc.

    S-3 - Moleculin Biotech, Inc. (0001659617) (Filer)

    3/27/26 4:01:09 PM ET
    $MBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Alector Inc.

    SCHEDULE 13G/A - Alector, Inc. (0001653087) (Subject)

    3/26/26 3:24:00 PM ET
    $ALEC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALEC
    $ASLN
    $BCEL
    $CNSP
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for GIMOTI

    Submission status for EVOKE PHARMA INC's drug GIMOTI (SUPPL-1) with active ingredient METOCLOPRAMIDE HYDROCHLORIDE has changed to 'Approval' on 01/14/2021. Application Category: NDA, Application Number: 209388, Application Classification: Labeling

    1/15/21 5:10:35 AM ET
    $EVOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALEC
    $ASLN
    $BCEL
    $CNSP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $ALEC
    $ASLN
    $BCEL
    $CNSP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $ALEC
    $ASLN
    $BCEL
    $CNSP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Collins Helen Louise

    4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)

    3/27/26 4:57:22 PM ET
    $ELVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Lowrance David L

    4 - Savara Inc (0001160308) (Issuer)

    3/20/26 4:16:03 PM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Collins Helen Louise

    4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)

    3/19/26 5:50:52 PM ET
    $ELVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Savara Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) for MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

    -- EMA Review of MOLBREEVI MAA Has Now Initiated, Decision Expected in Q1 2027 -- -- MOLBREEVI Biologics License Application (BLA) is Currently Under Priority Review with the U.S. Food and Drug Administration (FDA), with an Action Date of August 22, 2026 -- -- MOLBREEVI MAA Was Submitted to the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) in March 2026 -- Savara Inc. (NASDAQ:SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the EMA has validated the submission of the MOLBREEVI MAA in autoimmune PAP; the submission will now be reviewed by the Committee for Medicinal Products for Human Use (CHMP)

    3/30/26 8:05:00 AM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Moleculin Hits 45 Subject Enrollment Milestone, Triggering Final Countdown to Mid-2026 MIRACLE Trial Data Readout

    First Interim Unblinding of Pivotal AML Trial Now Imminent — Potentially the Most Important Data Moment in Company HistoryEarly Blinded Results Show 40% Remission Rate Across Difficult-to-Treat Patient PopulationEnrollment Accelerating Toward 90 Subject Threshold as Phase 3 Pathway Takes Shape HOUSTON, March 23, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), today announced that the 45th subject has been enrolled in its pivotal Phase 2B/3 MIRACLE trial evaluating Annamycin in combination with cytarabine (AnnAraC) for the treatment of adult subjects with relapsed or refractory acute myeloid leukemia (R/R AML). This milestone triggers the fin

    3/23/26 8:31:00 AM ET
    $MBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Initiating Coverage with a Valuation of $12.00/Share from Zacks Small-Cap Research

    Estrella Immunopharma, Inc. (NASDAQ:ESLA, ESLAW)) ("Estrella" or the "Company"), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced that Zacks Small-Cap Research ("Zacks SCR"), a division of Zacks Investment Research, has initiated coverage on the Company, assigning a valuation of $12.00 per share. The coverage report highlights the Company's differentiated ARTEMIS platform and encouraging early clinical data from the Phase I/II STARLIGHT-1 trial of EB103. "The recent $7.8 billion acquisition of Arcellx by Gilead Sciences underscores the premium that large biopharmaceutical compani

    3/23/26 8:00:00 AM ET
    $ESLA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Financial Officer Foster Jonathan P. covered exercise/tax liability with 1,715 shares, bought $100,000 worth of shares (270,270 units at $0.37) and converted options into 7,039 shares, increasing direct ownership by 2,298% to 287,587 units (SEC Form 4)

    4 - Moleculin Biotech, Inc. (0001659617) (Issuer)

    6/23/25 4:35:31 PM ET
    $MBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO and President Klemp Walter V bought $250,000 worth of shares (675,675 units at $0.37), converted options into 12,740 shares and covered exercise/tax liability with 3,104 shares, increasing direct ownership by 1,176% to 743,607 units (SEC Form 4)

    4 - Moleculin Biotech, Inc. (0001659617) (Issuer)

    6/23/25 4:35:11 PM ET
    $MBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Hawkins Richard J bought $98,572 worth of shares (48,225 units at $2.04), increasing direct ownership by 72% to 115,466 units (SEC Form 4)

    4 - Savara Inc (0001160308) (Issuer)

    6/23/25 2:39:22 PM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALEC
    $ASLN
    $BCEL
    $CNSP
    Leadership Updates

    Live Leadership Updates

    View All

    Enliven Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update

    Reported positive initial Phase 1b data for ELVN-001 in CML Initiation of the Phase 3 ENABLE-2 pivotal trial of ELVN-001 expected in the second half of 2026Key data readout, regulatory interactions, and operational catalysts throughout 2026Strong balance sheet with $463 million in cash, cash equivalents and marketable securities, which is expected to provide cash runway into the first half of 2029BOULDER, Colo., March 3, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today reported financial results for the fourth quarter and full year e

    3/3/26 4:05:00 PM ET
    $ELVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Enliven Therapeutics Bolsters Board to Prepare for Next Phase of Development

    Scott Garland, a seasoned biopharma executive with a strong track record of leading successful companies and drug launches, joins Enliven's Board of Directors Building on positive data reported in 2025, Enliven continues to prepare for Phase 3 trial initiation in 2026 and the commercialization of ELVN-001 BOULDER, Colo., Jan. 7, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced the appointment of Scott Garland to its Board of Directors and the planned resignation of Andrew Phillips, Ph.D., who has decided to step down, effec

    1/7/26 9:00:00 AM ET
    $ELVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alector Appoints Neil Berkley as Chief Financial Officer and Chief Business Officer

    SOUTH SAN FRANCISCO, Calif., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that Neil Berkley, who has served as Alector's Chief Business Officer (CBO) since March 2024, and CBO and Interim Chief Financial Officer (CFO) since June 2025, has been appointed CFO, effective December 10, 2025. Mr. Berkley will continue to serve as CBO. "Neil has demonstrated exceptional leadership, judgment, strategic insight, and an unwavering commitment to Alector's mission," said Arnon Rosenthal, Ph.D., Chief Executive Officer of Alector. "His

    12/12/25 4:05:00 PM ET
    $ALEC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALEC
    $ASLN
    $BCEL
    $CNSP
    Financials

    Live finance-specific insights

    View All

    Moleculin Reports Full Year 2025 Financial Results and Confirms Highly Anticipated 45-Patient Interim Data Unblinding in Pivotal MIRACLE Trial On Track for Mid-2026

    Miracle Trial Preliminary Blinded CRc Rate of 40% in First 30 Patients Suggests Encouraging Early Results in Relapsed/Refractory AML HOUSTON, March 19, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), today reported financial results for the year ended December 31, 2025 and provided a clinical update highlighting rapid progress toward a major upcoming milestone in its pivotal MIRACLE trial of Annamycin in combination with cytarabine for the treatment of adult patients with acute myeloid leukemia (AML) who are refractory to or relapsed (R/R) after induction therapy (R/R AML). "With the MIRACLE trial rapidly progressing and the first MIRACLE i

    3/19/26 8:36:00 AM ET
    $MBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alector Reports Second Quarter 2025 Financial Results and Provides Business Update

    On track to report topline data by mid-Q4 2025 from the pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN, a severe, rare form of dementia with no approved treatments Ongoing Phase 2 PROGRESS-AD trial of AL101 in early Alzheimer's disease expected to complete in 2026 Continuing to progress Alector Brain Carrier programs, including the company's anti-amyloid beta antibody, engineered GCase enzyme replacement therapy, and anti-tau siRNA $307.3 million in cash, cash equivalents, and investments provides runway into the second half of 2027 Management to host conference call and webcast today at 4:30 p.m. ET/1:30 p.m. PT SOUTH SAN FRANCISCO, Calif., Aug. 07, 2025 (GLOBE NE

    8/7/25 4:05:00 PM ET
    $ALEC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Alector to Host Second Quarter and Mid-Year 2025 Earnings Conference Call

    SOUTH SAN FRANCISCO, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced it will host a conference call and webcast on Thursday, August 7, 2025, at 4:30 p.m. ET to discuss results for the second quarter ended June 30, 2025, and provide a mid-year business update. The call will feature remarks from Ryan Darby, M.D., Associate Professor of Neurology and Director of the Frontotemporal Dementia Clinic at Vanderbilt University Medical Center, who will speak on the unmet need in frontotemporal dementia. A press release deta

    7/31/25 4:05:00 PM ET
    $ALEC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALEC
    $ASLN
    $BCEL
    $CNSP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Alector Inc.

    SC 13G - Alector, Inc. (0001653087) (Subject)

    12/6/24 5:30:28 PM ET
    $ALEC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Savara Inc.

    SC 13G - Savara Inc (0001160308) (Subject)

    11/27/24 11:01:58 AM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Savara Inc.

    SC 13G/A - Savara Inc (0001160308) (Subject)

    11/14/24 5:48:34 PM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care